Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
Moderna’s MRNA-Q personalized mRNA cancer therapy, developed with Merck MRK-N , reduced the risk of recurrence and spread of skin cancer in a late-stage trial when combined with immunotherapy drug Keytruda, sending Moderna’s shares up around 150 per cent to multi-year highs.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.theglobeandmail.com — the content belongs to The Globe and Mail.
